nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranitidine—CYP3A4—bone cancer	0.744	1	CbGaD
Ranitidine—SLC22A8—Methotrexate—bone cancer	0.0422	0.384	CbGbCtD
Ranitidine—ABCB1—Cisplatin—bone cancer	0.0202	0.184	CbGbCtD
Ranitidine—ABCB1—Doxorubicin—bone cancer	0.0135	0.123	CbGbCtD
Ranitidine—ABCB1—Methotrexate—bone cancer	0.0131	0.119	CbGbCtD
Ranitidine—CYP2D6—Doxorubicin—bone cancer	0.0127	0.116	CbGbCtD
Ranitidine—CYP3A4—Doxorubicin—bone cancer	0.00809	0.0738	CbGbCtD
Ranitidine—Nephrotoxicity—Cisplatin—bone cancer	0.00466	0.0386	CcSEcCtD
Ranitidine—Nephropathy toxic—Cisplatin—bone cancer	0.00258	0.0214	CcSEcCtD
Ranitidine—Serum creatinine increased—Cisplatin—bone cancer	0.00241	0.02	CcSEcCtD
Ranitidine—Loss of libido—Methotrexate—bone cancer	0.00176	0.0146	CcSEcCtD
Ranitidine—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00174	0.068	CbGpPWpGaD
Ranitidine—Nephropathy—Methotrexate—bone cancer	0.00171	0.0142	CcSEcCtD
Ranitidine—Pain—Carboplatin—bone cancer	0.00154	0.0128	CcSEcCtD
Ranitidine—Hepatocellular injury—Cisplatin—bone cancer	0.00148	0.0123	CcSEcCtD
Ranitidine—Wheezing—Cisplatin—bone cancer	0.00144	0.0119	CcSEcCtD
Ranitidine—Body temperature increased—Carboplatin—bone cancer	0.00143	0.0118	CcSEcCtD
Ranitidine—Serum creatinine increased—Epirubicin—bone cancer	0.00124	0.0103	CcSEcCtD
Ranitidine—Bone marrow depression—Methotrexate—bone cancer	0.0012	0.00999	CcSEcCtD
Ranitidine—Liver disorder—Methotrexate—bone cancer	0.00119	0.00989	CcSEcCtD
Ranitidine—Haematemesis—Methotrexate—bone cancer	0.00117	0.00971	CcSEcCtD
Ranitidine—Serum creatinine increased—Doxorubicin—bone cancer	0.00114	0.00949	CcSEcCtD
Ranitidine—Bone marrow depression—Epirubicin—bone cancer	0.00113	0.00935	CcSEcCtD
Ranitidine—Haematemesis—Epirubicin—bone cancer	0.0011	0.00908	CcSEcCtD
Ranitidine—Bone marrow depression—Doxorubicin—bone cancer	0.00104	0.00865	CcSEcCtD
Ranitidine—Haematemesis—Doxorubicin—bone cancer	0.00101	0.00841	CcSEcCtD
Ranitidine—Blood creatinine increased—Cisplatin—bone cancer	0.00101	0.00836	CcSEcCtD
Ranitidine—Breast disorder—Cisplatin—bone cancer	0.000972	0.00806	CcSEcCtD
Ranitidine—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000948	0.037	CbGpPWpGaD
Ranitidine—Pancreatitis—Cisplatin—bone cancer	0.000912	0.00756	CcSEcCtD
Ranitidine—Blood disorder—Epirubicin—bone cancer	0.000911	0.00756	CcSEcCtD
Ranitidine—Abdominal discomfort—Cisplatin—bone cancer	0.000891	0.00739	CcSEcCtD
Ranitidine—Delirium—Epirubicin—bone cancer	0.000885	0.00734	CcSEcCtD
Ranitidine—Pancytopenia—Cisplatin—bone cancer	0.000883	0.00732	CcSEcCtD
Ranitidine—Jaundice cholestatic—Epirubicin—bone cancer	0.000866	0.00718	CcSEcCtD
Ranitidine—Blood disorder—Doxorubicin—bone cancer	0.000843	0.00699	CcSEcCtD
Ranitidine—Ventricular extrasystoles—Epirubicin—bone cancer	0.000843	0.00699	CcSEcCtD
Ranitidine—Vasculitis—Methotrexate—bone cancer	0.000833	0.00691	CcSEcCtD
Ranitidine—Delirium—Doxorubicin—bone cancer	0.000819	0.00679	CcSEcCtD
Ranitidine—Dyskinesia—Epirubicin—bone cancer	0.00081	0.00672	CcSEcCtD
Ranitidine—Jaundice cholestatic—Doxorubicin—bone cancer	0.000802	0.00665	CcSEcCtD
Ranitidine—Atrioventricular block—Epirubicin—bone cancer	0.000785	0.00651	CcSEcCtD
Ranitidine—Ventricular extrasystoles—Doxorubicin—bone cancer	0.00078	0.00647	CcSEcCtD
Ranitidine—Musculoskeletal pain—Epirubicin—bone cancer	0.00077	0.00639	CcSEcCtD
Ranitidine—Aplastic anaemia—Methotrexate—bone cancer	0.000764	0.00633	CcSEcCtD
Ranitidine—Hepatocellular injury—Epirubicin—bone cancer	0.000761	0.00631	CcSEcCtD
Ranitidine—Bradycardia—Cisplatin—bone cancer	0.000758	0.00628	CcSEcCtD
Ranitidine—Dermatitis contact—Epirubicin—bone cancer	0.000752	0.00624	CcSEcCtD
Ranitidine—Dyskinesia—Doxorubicin—bone cancer	0.000749	0.00621	CcSEcCtD
Ranitidine—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000733	0.0286	CbGpPWpGaD
Ranitidine—Gynaecomastia—Methotrexate—bone cancer	0.000728	0.00603	CcSEcCtD
Ranitidine—Atrioventricular block—Doxorubicin—bone cancer	0.000726	0.00602	CcSEcCtD
Ranitidine—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000719	0.0281	CbGpPWpGaD
Ranitidine—Aplastic anaemia—Epirubicin—bone cancer	0.000715	0.00593	CcSEcCtD
Ranitidine—Musculoskeletal pain—Doxorubicin—bone cancer	0.000713	0.00591	CcSEcCtD
Ranitidine—Hepatocellular injury—Doxorubicin—bone cancer	0.000704	0.00584	CcSEcCtD
Ranitidine—Dermatitis contact—Doxorubicin—bone cancer	0.000696	0.00577	CcSEcCtD
Ranitidine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000677	0.0265	CbGpPWpGaD
Ranitidine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000674	0.0263	CbGpPWpGaD
Ranitidine—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000673	0.0263	CbGpPWpGaD
Ranitidine—Photosensitivity—Methotrexate—bone cancer	0.000672	0.00558	CcSEcCtD
Ranitidine—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000672	0.0262	CbGpPWpGaD
Ranitidine—Arrhythmia—Cisplatin—bone cancer	0.000665	0.00551	CcSEcCtD
Ranitidine—Aplastic anaemia—Doxorubicin—bone cancer	0.000661	0.00548	CcSEcCtD
Ranitidine—Alopecia—Cisplatin—bone cancer	0.000658	0.00545	CcSEcCtD
Ranitidine—Hepatic failure—Methotrexate—bone cancer	0.000657	0.00545	CcSEcCtD
Ranitidine—Erythema—Cisplatin—bone cancer	0.000648	0.00537	CcSEcCtD
Ranitidine—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000639	0.0249	CbGpPWpGaD
Ranitidine—Photosensitivity—Epirubicin—bone cancer	0.000629	0.00522	CcSEcCtD
Ranitidine—Hepatic failure—Epirubicin—bone cancer	0.000615	0.0051	CcSEcCtD
Ranitidine—Vision blurred—Cisplatin—bone cancer	0.000611	0.00506	CcSEcCtD
Ranitidine—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000609	0.0238	CbGpPWpGaD
Ranitidine—Ill-defined disorder—Cisplatin—bone cancer	0.000601	0.00498	CcSEcCtD
Ranitidine—Anaemia—Cisplatin—bone cancer	0.000599	0.00497	CcSEcCtD
Ranitidine—Malaise—Cisplatin—bone cancer	0.000584	0.00484	CcSEcCtD
Ranitidine—Photosensitivity—Doxorubicin—bone cancer	0.000582	0.00483	CcSEcCtD
Ranitidine—Leukopenia—Cisplatin—bone cancer	0.00058	0.00481	CcSEcCtD
Ranitidine—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000571	0.0223	CbGpPWpGaD
Ranitidine—Hepatic failure—Doxorubicin—bone cancer	0.000569	0.00472	CcSEcCtD
Ranitidine—Myalgia—Cisplatin—bone cancer	0.000552	0.00457	CcSEcCtD
Ranitidine—Discomfort—Cisplatin—bone cancer	0.000545	0.00452	CcSEcCtD
Ranitidine—Breast disorder—Methotrexate—bone cancer	0.000534	0.00442	CcSEcCtD
Ranitidine—Anaphylactic shock—Cisplatin—bone cancer	0.000529	0.00438	CcSEcCtD
Ranitidine—Cardiac arrest—Epirubicin—bone cancer	0.000525	0.00436	CcSEcCtD
Ranitidine—Thrombocytopenia—Cisplatin—bone cancer	0.000518	0.00429	CcSEcCtD
Ranitidine—Blood creatinine increased—Epirubicin—bone cancer	0.000518	0.00429	CcSEcCtD
Ranitidine—Tachycardia—Cisplatin—bone cancer	0.000516	0.00428	CcSEcCtD
Ranitidine—Hyperhidrosis—Cisplatin—bone cancer	0.000511	0.00424	CcSEcCtD
Ranitidine—Eosinophilia—Methotrexate—bone cancer	0.000505	0.00419	CcSEcCtD
Ranitidine—Abdominal pain upper—Epirubicin—bone cancer	0.000505	0.00418	CcSEcCtD
Ranitidine—Pancreatitis—Methotrexate—bone cancer	0.0005	0.00415	CcSEcCtD
Ranitidine—Breast disorder—Epirubicin—bone cancer	0.000499	0.00414	CcSEcCtD
Ranitidine—Hypotension—Cisplatin—bone cancer	0.000494	0.0041	CcSEcCtD
Ranitidine—Abdominal discomfort—Methotrexate—bone cancer	0.000489	0.00406	CcSEcCtD
Ranitidine—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000487	0.00404	CcSEcCtD
Ranitidine—Cardiac arrest—Doxorubicin—bone cancer	0.000486	0.00403	CcSEcCtD
Ranitidine—Pancytopenia—Methotrexate—bone cancer	0.000485	0.00402	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000482	0.00399	CcSEcCtD
Ranitidine—Blood creatinine increased—Doxorubicin—bone cancer	0.000479	0.00397	CcSEcCtD
Ranitidine—Dysphagia—Epirubicin—bone cancer	0.000478	0.00396	CcSEcCtD
Ranitidine—Neutropenia—Methotrexate—bone cancer	0.000477	0.00396	CcSEcCtD
Ranitidine—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000477	0.0186	CbGpPWpGaD
Ranitidine—Eosinophilia—Epirubicin—bone cancer	0.000473	0.00392	CcSEcCtD
Ranitidine—Dyspnoea—Cisplatin—bone cancer	0.000471	0.00391	CcSEcCtD
Ranitidine—Erectile dysfunction—Methotrexate—bone cancer	0.00047	0.0039	CcSEcCtD
Ranitidine—Pancreatitis—Epirubicin—bone cancer	0.000468	0.00388	CcSEcCtD
Ranitidine—Abdominal pain upper—Doxorubicin—bone cancer	0.000467	0.00387	CcSEcCtD
Ranitidine—Photosensitivity reaction—Methotrexate—bone cancer	0.000466	0.00386	CcSEcCtD
Ranitidine—Angina pectoris—Epirubicin—bone cancer	0.000465	0.00386	CcSEcCtD
Ranitidine—Breast disorder—Doxorubicin—bone cancer	0.000462	0.00383	CcSEcCtD
Ranitidine—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000458	0.0179	CbGpPWpGaD
Ranitidine—Pneumonia—Methotrexate—bone cancer	0.000458	0.00379	CcSEcCtD
Ranitidine—Pancytopenia—Epirubicin—bone cancer	0.000454	0.00376	CcSEcCtD
Ranitidine—Pain—Cisplatin—bone cancer	0.000452	0.00375	CcSEcCtD
Ranitidine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000451	0.00374	CcSEcCtD
Ranitidine—Neutropenia—Epirubicin—bone cancer	0.000447	0.0037	CcSEcCtD
Ranitidine—Dysphagia—Doxorubicin—bone cancer	0.000442	0.00366	CcSEcCtD
Ranitidine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000441	0.0172	CbGpPWpGaD
Ranitidine—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.00044	0.0172	CbGpPWpGaD
Ranitidine—Eosinophilia—Doxorubicin—bone cancer	0.000437	0.00363	CcSEcCtD
Ranitidine—Sweating—Methotrexate—bone cancer	0.000436	0.00362	CcSEcCtD
Ranitidine—Photosensitivity reaction—Epirubicin—bone cancer	0.000436	0.00361	CcSEcCtD
Ranitidine—Feeling abnormal—Cisplatin—bone cancer	0.000436	0.00361	CcSEcCtD
Ranitidine—Pancreatitis—Doxorubicin—bone cancer	0.000433	0.00359	CcSEcCtD
Ranitidine—Weight decreased—Epirubicin—bone cancer	0.000432	0.00358	CcSEcCtD
Ranitidine—Angina pectoris—Doxorubicin—bone cancer	0.00043	0.00357	CcSEcCtD
Ranitidine—Pneumonia—Epirubicin—bone cancer	0.000428	0.00355	CcSEcCtD
Ranitidine—Agranulocytosis—Methotrexate—bone cancer	0.000425	0.00352	CcSEcCtD
Ranitidine—Pancytopenia—Doxorubicin—bone cancer	0.00042	0.00348	CcSEcCtD
Ranitidine—Body temperature increased—Cisplatin—bone cancer	0.000418	0.00347	CcSEcCtD
Ranitidine—Jaundice—Epirubicin—bone cancer	0.000415	0.00344	CcSEcCtD
Ranitidine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000415	0.0162	CbGpPWpGaD
Ranitidine—Neutropenia—Doxorubicin—bone cancer	0.000413	0.00343	CcSEcCtD
Ranitidine—Hepatitis—Methotrexate—bone cancer	0.000408	0.00339	CcSEcCtD
Ranitidine—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000408	0.0159	CbGpPWpGaD
Ranitidine—Sweating—Epirubicin—bone cancer	0.000408	0.00338	CcSEcCtD
Ranitidine—Photosensitivity reaction—Doxorubicin—bone cancer	0.000403	0.00334	CcSEcCtD
Ranitidine—Weight decreased—Doxorubicin—bone cancer	0.0004	0.00331	CcSEcCtD
Ranitidine—Agranulocytosis—Epirubicin—bone cancer	0.000397	0.00329	CcSEcCtD
Ranitidine—Pneumonia—Doxorubicin—bone cancer	0.000396	0.00329	CcSEcCtD
Ranitidine—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000393	0.0154	CbGpPWpGaD
Ranitidine—Hypersensitivity—Cisplatin—bone cancer	0.00039	0.00323	CcSEcCtD
Ranitidine—Bradycardia—Epirubicin—bone cancer	0.000389	0.00323	CcSEcCtD
Ranitidine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000389	0.0152	CbGpPWpGaD
Ranitidine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000387	0.0151	CbGpPWpGaD
Ranitidine—Erythema multiforme—Methotrexate—bone cancer	0.000386	0.0032	CcSEcCtD
Ranitidine—Jaundice—Doxorubicin—bone cancer	0.000384	0.00318	CcSEcCtD
Ranitidine—Hepatitis—Epirubicin—bone cancer	0.000382	0.00317	CcSEcCtD
Ranitidine—Sweating—Doxorubicin—bone cancer	0.000378	0.00313	CcSEcCtD
Ranitidine—Agranulocytosis—Doxorubicin—bone cancer	0.000368	0.00305	CcSEcCtD
Ranitidine—Diarrhoea—Cisplatin—bone cancer	0.000362	0.003	CcSEcCtD
Ranitidine—Erythema multiforme—Epirubicin—bone cancer	0.000361	0.003	CcSEcCtD
Ranitidine—Alopecia—Methotrexate—bone cancer	0.000361	0.00299	CcSEcCtD
Ranitidine—Bradycardia—Doxorubicin—bone cancer	0.00036	0.00299	CcSEcCtD
Ranitidine—Erythema—Methotrexate—bone cancer	0.000356	0.00295	CcSEcCtD
Ranitidine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000354	0.0138	CbGpPWpGaD
Ranitidine—Hepatitis—Doxorubicin—bone cancer	0.000354	0.00293	CcSEcCtD
Ranitidine—Arrhythmia—Epirubicin—bone cancer	0.000341	0.00283	CcSEcCtD
Ranitidine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.00034	0.0133	CbGpPWpGaD
Ranitidine—Alopecia—Epirubicin—bone cancer	0.000338	0.0028	CcSEcCtD
Ranitidine—Vomiting—Cisplatin—bone cancer	0.000336	0.00279	CcSEcCtD
Ranitidine—Vision blurred—Methotrexate—bone cancer	0.000335	0.00278	CcSEcCtD
Ranitidine—Erythema multiforme—Doxorubicin—bone cancer	0.000334	0.00277	CcSEcCtD
Ranitidine—Rash—Cisplatin—bone cancer	0.000333	0.00276	CcSEcCtD
Ranitidine—Dermatitis—Cisplatin—bone cancer	0.000333	0.00276	CcSEcCtD
Ranitidine—Erythema—Epirubicin—bone cancer	0.000333	0.00276	CcSEcCtD
Ranitidine—Ill-defined disorder—Methotrexate—bone cancer	0.00033	0.00274	CcSEcCtD
Ranitidine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00033	0.0129	CbGpPWpGaD
Ranitidine—Anaemia—Methotrexate—bone cancer	0.000329	0.00272	CcSEcCtD
Ranitidine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000325	0.0127	CbGpPWpGaD
Ranitidine—Malaise—Methotrexate—bone cancer	0.000321	0.00266	CcSEcCtD
Ranitidine—Vertigo—Methotrexate—bone cancer	0.000319	0.00265	CcSEcCtD
Ranitidine—Leukopenia—Methotrexate—bone cancer	0.000318	0.00264	CcSEcCtD
Ranitidine—Arrhythmia—Doxorubicin—bone cancer	0.000316	0.00262	CcSEcCtD
Ranitidine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000316	0.0123	CbGpPWpGaD
Ranitidine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000314	0.0123	CbGpPWpGaD
Ranitidine—Nausea—Cisplatin—bone cancer	0.000314	0.0026	CcSEcCtD
Ranitidine—Vision blurred—Epirubicin—bone cancer	0.000314	0.0026	CcSEcCtD
Ranitidine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000313	0.0122	CbGpPWpGaD
Ranitidine—Alopecia—Doxorubicin—bone cancer	0.000313	0.00259	CcSEcCtD
Ranitidine—Ill-defined disorder—Epirubicin—bone cancer	0.000309	0.00256	CcSEcCtD
Ranitidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000309	0.0121	CbGpPWpGaD
Ranitidine—Erythema—Doxorubicin—bone cancer	0.000308	0.00255	CcSEcCtD
Ranitidine—Anaemia—Epirubicin—bone cancer	0.000308	0.00255	CcSEcCtD
Ranitidine—Agitation—Epirubicin—bone cancer	0.000306	0.00254	CcSEcCtD
Ranitidine—Chest pain—Methotrexate—bone cancer	0.000303	0.00251	CcSEcCtD
Ranitidine—Arthralgia—Methotrexate—bone cancer	0.000303	0.00251	CcSEcCtD
Ranitidine—Myalgia—Methotrexate—bone cancer	0.000303	0.00251	CcSEcCtD
Ranitidine—Malaise—Epirubicin—bone cancer	0.0003	0.00249	CcSEcCtD
Ranitidine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.0003	0.0117	CbGpPWpGaD
Ranitidine—Discomfort—Methotrexate—bone cancer	0.000299	0.00248	CcSEcCtD
Ranitidine—Vertigo—Epirubicin—bone cancer	0.000299	0.00248	CcSEcCtD
Ranitidine—Leukopenia—Epirubicin—bone cancer	0.000298	0.00247	CcSEcCtD
Ranitidine—Confusional state—Methotrexate—bone cancer	0.000293	0.00243	CcSEcCtD
Ranitidine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00029	0.0113	CbGpPWpGaD
Ranitidine—Anaphylactic shock—Methotrexate—bone cancer	0.00029	0.00241	CcSEcCtD
Ranitidine—Vision blurred—Doxorubicin—bone cancer	0.00029	0.00241	CcSEcCtD
Ranitidine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000287	0.0112	CbGpPWpGaD
Ranitidine—Ill-defined disorder—Doxorubicin—bone cancer	0.000286	0.00237	CcSEcCtD
Ranitidine—Anaemia—Doxorubicin—bone cancer	0.000285	0.00236	CcSEcCtD
Ranitidine—Thrombocytopenia—Methotrexate—bone cancer	0.000284	0.00236	CcSEcCtD
Ranitidine—Chest pain—Epirubicin—bone cancer	0.000283	0.00235	CcSEcCtD
Ranitidine—Myalgia—Epirubicin—bone cancer	0.000283	0.00235	CcSEcCtD
Ranitidine—Arthralgia—Epirubicin—bone cancer	0.000283	0.00235	CcSEcCtD
Ranitidine—Agitation—Doxorubicin—bone cancer	0.000283	0.00235	CcSEcCtD
Ranitidine—Hyperhidrosis—Methotrexate—bone cancer	0.000281	0.00233	CcSEcCtD
Ranitidine—Discomfort—Epirubicin—bone cancer	0.00028	0.00232	CcSEcCtD
Ranitidine—Malaise—Doxorubicin—bone cancer	0.000278	0.0023	CcSEcCtD
Ranitidine—Vertigo—Doxorubicin—bone cancer	0.000277	0.00229	CcSEcCtD
Ranitidine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000276	0.0108	CbGpPWpGaD
Ranitidine—Leukopenia—Doxorubicin—bone cancer	0.000276	0.00229	CcSEcCtD
Ranitidine—Confusional state—Epirubicin—bone cancer	0.000274	0.00227	CcSEcCtD
Ranitidine—Anaphylactic shock—Epirubicin—bone cancer	0.000272	0.00225	CcSEcCtD
Ranitidine—Hypotension—Methotrexate—bone cancer	0.000271	0.00225	CcSEcCtD
Ranitidine—Thrombocytopenia—Epirubicin—bone cancer	0.000266	0.0022	CcSEcCtD
Ranitidine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000265	0.0104	CbGpPWpGaD
Ranitidine—Tachycardia—Epirubicin—bone cancer	0.000265	0.0022	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000264	0.00219	CcSEcCtD
Ranitidine—Hyperhidrosis—Epirubicin—bone cancer	0.000263	0.00218	CcSEcCtD
Ranitidine—Insomnia—Methotrexate—bone cancer	0.000262	0.00218	CcSEcCtD
Ranitidine—Chest pain—Doxorubicin—bone cancer	0.000262	0.00217	CcSEcCtD
Ranitidine—Myalgia—Doxorubicin—bone cancer	0.000262	0.00217	CcSEcCtD
Ranitidine—Arthralgia—Doxorubicin—bone cancer	0.000262	0.00217	CcSEcCtD
Ranitidine—Discomfort—Doxorubicin—bone cancer	0.000259	0.00215	CcSEcCtD
Ranitidine—Dyspnoea—Methotrexate—bone cancer	0.000259	0.00215	CcSEcCtD
Ranitidine—Somnolence—Methotrexate—bone cancer	0.000258	0.00214	CcSEcCtD
Ranitidine—Hypotension—Epirubicin—bone cancer	0.000254	0.0021	CcSEcCtD
Ranitidine—Confusional state—Doxorubicin—bone cancer	0.000253	0.0021	CcSEcCtD
Ranitidine—Anaphylactic shock—Doxorubicin—bone cancer	0.000251	0.00208	CcSEcCtD
Ranitidine—Pain—Methotrexate—bone cancer	0.000248	0.00206	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000247	0.00205	CcSEcCtD
Ranitidine—Thrombocytopenia—Doxorubicin—bone cancer	0.000246	0.00204	CcSEcCtD
Ranitidine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000246	0.0096	CbGpPWpGaD
Ranitidine—Insomnia—Epirubicin—bone cancer	0.000246	0.00204	CcSEcCtD
Ranitidine—Tachycardia—Doxorubicin—bone cancer	0.000245	0.00203	CcSEcCtD
Ranitidine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000243	0.00949	CbGpPWpGaD
Ranitidine—Hyperhidrosis—Doxorubicin—bone cancer	0.000243	0.00201	CcSEcCtD
Ranitidine—Dyspnoea—Epirubicin—bone cancer	0.000242	0.00201	CcSEcCtD
Ranitidine—Somnolence—Epirubicin—bone cancer	0.000241	0.002	CcSEcCtD
Ranitidine—Feeling abnormal—Methotrexate—bone cancer	0.000239	0.00198	CcSEcCtD
Ranitidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000238	0.00931	CbGpPWpGaD
Ranitidine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000237	0.00926	CbGpPWpGaD
Ranitidine—Hypotension—Doxorubicin—bone cancer	0.000235	0.00195	CcSEcCtD
Ranitidine—Pain—Epirubicin—bone cancer	0.000232	0.00193	CcSEcCtD
Ranitidine—Constipation—Epirubicin—bone cancer	0.000232	0.00193	CcSEcCtD
Ranitidine—Urticaria—Methotrexate—bone cancer	0.000231	0.00191	CcSEcCtD
Ranitidine—Abdominal pain—Methotrexate—bone cancer	0.000229	0.0019	CcSEcCtD
Ranitidine—Body temperature increased—Methotrexate—bone cancer	0.000229	0.0019	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000229	0.0019	CcSEcCtD
Ranitidine—Insomnia—Doxorubicin—bone cancer	0.000227	0.00188	CcSEcCtD
Ranitidine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000226	0.00882	CbGpPWpGaD
Ranitidine—Dyspnoea—Doxorubicin—bone cancer	0.000224	0.00186	CcSEcCtD
Ranitidine—Feeling abnormal—Epirubicin—bone cancer	0.000224	0.00186	CcSEcCtD
Ranitidine—Somnolence—Doxorubicin—bone cancer	0.000223	0.00185	CcSEcCtD
Ranitidine—Urticaria—Epirubicin—bone cancer	0.000216	0.00179	CcSEcCtD
Ranitidine—Constipation—Doxorubicin—bone cancer	0.000215	0.00178	CcSEcCtD
Ranitidine—Pain—Doxorubicin—bone cancer	0.000215	0.00178	CcSEcCtD
Ranitidine—Abdominal pain—Epirubicin—bone cancer	0.000215	0.00178	CcSEcCtD
Ranitidine—Body temperature increased—Epirubicin—bone cancer	0.000215	0.00178	CcSEcCtD
Ranitidine—Hypersensitivity—Methotrexate—bone cancer	0.000214	0.00177	CcSEcCtD
Ranitidine—Feeling abnormal—Doxorubicin—bone cancer	0.000207	0.00172	CcSEcCtD
Ranitidine—Pruritus—Methotrexate—bone cancer	0.000205	0.0017	CcSEcCtD
Ranitidine—Hypersensitivity—Epirubicin—bone cancer	0.0002	0.00166	CcSEcCtD
Ranitidine—Urticaria—Doxorubicin—bone cancer	0.0002	0.00166	CcSEcCtD
Ranitidine—Abdominal pain—Doxorubicin—bone cancer	0.000199	0.00165	CcSEcCtD
Ranitidine—Body temperature increased—Doxorubicin—bone cancer	0.000199	0.00165	CcSEcCtD
Ranitidine—Diarrhoea—Methotrexate—bone cancer	0.000199	0.00165	CcSEcCtD
Ranitidine—Pruritus—Epirubicin—bone cancer	0.000192	0.00159	CcSEcCtD
Ranitidine—Dizziness—Methotrexate—bone cancer	0.000192	0.00159	CcSEcCtD
Ranitidine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00019	0.00742	CbGpPWpGaD
Ranitidine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00019	0.00741	CbGpPWpGaD
Ranitidine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000188	0.00733	CbGpPWpGaD
Ranitidine—HRH2—GPCR ligand binding—GRM4—bone cancer	0.000186	0.00728	CbGpPWpGaD
Ranitidine—Diarrhoea—Epirubicin—bone cancer	0.000186	0.00154	CcSEcCtD
Ranitidine—Hypersensitivity—Doxorubicin—bone cancer	0.000185	0.00154	CcSEcCtD
Ranitidine—Vomiting—Methotrexate—bone cancer	0.000185	0.00153	CcSEcCtD
Ranitidine—Rash—Methotrexate—bone cancer	0.000183	0.00152	CcSEcCtD
Ranitidine—Dermatitis—Methotrexate—bone cancer	0.000183	0.00152	CcSEcCtD
Ranitidine—Headache—Methotrexate—bone cancer	0.000182	0.00151	CcSEcCtD
Ranitidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00018	0.00704	CbGpPWpGaD
Ranitidine—Dizziness—Epirubicin—bone cancer	0.00018	0.00149	CcSEcCtD
Ranitidine—Pruritus—Doxorubicin—bone cancer	0.000178	0.00147	CcSEcCtD
Ranitidine—Vomiting—Epirubicin—bone cancer	0.000173	0.00143	CcSEcCtD
Ranitidine—Nausea—Methotrexate—bone cancer	0.000172	0.00143	CcSEcCtD
Ranitidine—Diarrhoea—Doxorubicin—bone cancer	0.000172	0.00143	CcSEcCtD
Ranitidine—Rash—Epirubicin—bone cancer	0.000171	0.00142	CcSEcCtD
Ranitidine—Dermatitis—Epirubicin—bone cancer	0.000171	0.00142	CcSEcCtD
Ranitidine—Headache—Epirubicin—bone cancer	0.00017	0.00141	CcSEcCtD
Ranitidine—Dizziness—Doxorubicin—bone cancer	0.000166	0.00138	CcSEcCtD
Ranitidine—HRH2—GPCR ligand binding—GRM1—bone cancer	0.000162	0.00631	CbGpPWpGaD
Ranitidine—Nausea—Epirubicin—bone cancer	0.000161	0.00134	CcSEcCtD
Ranitidine—Vomiting—Doxorubicin—bone cancer	0.00016	0.00132	CcSEcCtD
Ranitidine—Rash—Doxorubicin—bone cancer	0.000158	0.00131	CcSEcCtD
Ranitidine—Dermatitis—Doxorubicin—bone cancer	0.000158	0.00131	CcSEcCtD
Ranitidine—Headache—Doxorubicin—bone cancer	0.000157	0.00131	CcSEcCtD
Ranitidine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000155	0.00607	CbGpPWpGaD
Ranitidine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000154	0.00602	CbGpPWpGaD
Ranitidine—Nausea—Doxorubicin—bone cancer	0.000149	0.00124	CcSEcCtD
Ranitidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000147	0.00574	CbGpPWpGaD
Ranitidine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000145	0.00566	CbGpPWpGaD
Ranitidine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000142	0.00553	CbGpPWpGaD
Ranitidine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000135	0.00528	CbGpPWpGaD
Ranitidine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000133	0.00521	CbGpPWpGaD
Ranitidine—SLC22A8—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000125	0.00487	CbGpPWpGaD
Ranitidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000119	0.00465	CbGpPWpGaD
Ranitidine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000114	0.00447	CbGpPWpGaD
Ranitidine—HRH2—GPCR ligand binding—SMO—bone cancer	0.000114	0.00445	CbGpPWpGaD
Ranitidine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000113	0.00441	CbGpPWpGaD
Ranitidine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00011	0.00428	CbGpPWpGaD
Ranitidine—SLC22A8—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000108	0.0042	CbGpPWpGaD
Ranitidine—HRH2—GPCR downstream signaling—RGS1—bone cancer	0.000105	0.00411	CbGpPWpGaD
Ranitidine—HRH2—GPCR downstream signaling—GRM4—bone cancer	0.000105	0.00411	CbGpPWpGaD
Ranitidine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	9.84e-05	0.00384	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—GRM4—bone cancer	9.57e-05	0.00374	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—RGS1—bone cancer	9.57e-05	0.00374	CbGpPWpGaD
Ranitidine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.28e-05	0.00363	CbGpPWpGaD
Ranitidine—HRH2—GPCR downstream signaling—GRM1—bone cancer	9.13e-05	0.00357	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—GRM1—bone cancer	8.29e-05	0.00324	CbGpPWpGaD
Ranitidine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	8.18e-05	0.0032	CbGpPWpGaD
Ranitidine—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.08e-05	0.00316	CbGpPWpGaD
Ranitidine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	8.07e-05	0.00315	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	8.06e-05	0.00315	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	7.63e-05	0.00298	CbGpPWpGaD
Ranitidine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	7.53e-05	0.00294	CbGpPWpGaD
Ranitidine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	7.21e-05	0.00282	CbGpPWpGaD
Ranitidine—CYP3A5—Biological oxidations—GSTP1—bone cancer	7e-05	0.00273	CbGpPWpGaD
Ranitidine—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.97e-05	0.00272	CbGpPWpGaD
Ranitidine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	6.9e-05	0.0027	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.85e-05	0.00268	CbGpPWpGaD
Ranitidine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	6.51e-05	0.00254	CbGpPWpGaD
Ranitidine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	6.33e-05	0.00247	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—NDUFA12—bone cancer	6.32e-05	0.00247	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	6.27e-05	0.00245	CbGpPWpGaD
Ranitidine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	6.24e-05	0.00244	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	6.24e-05	0.00244	CbGpPWpGaD
Ranitidine—HRH2—GPCR downstream signaling—GNA11—bone cancer	5.89e-05	0.0023	CbGpPWpGaD
Ranitidine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	5.87e-05	0.00229	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—SMO—bone cancer	5.84e-05	0.00228	CbGpPWpGaD
Ranitidine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	5.82e-05	0.00227	CbGpPWpGaD
Ranitidine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	5.74e-05	0.00224	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.68e-05	0.00222	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	5.66e-05	0.00221	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—GRM4—bone cancer	5.65e-05	0.00221	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—RGS1—bone cancer	5.65e-05	0.00221	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.6e-05	0.00219	CbGpPWpGaD
Ranitidine—CYP2C19—Biological oxidations—GSTP1—bone cancer	5.41e-05	0.00211	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—GNA11—bone cancer	5.34e-05	0.00209	CbGpPWpGaD
Ranitidine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	5.34e-05	0.00208	CbGpPWpGaD
Ranitidine—HRH2—GPCR downstream signaling—IL3—bone cancer	5.34e-05	0.00208	CbGpPWpGaD
Ranitidine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.31e-05	0.00207	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—NT5C3A—bone cancer	5.23e-05	0.00204	CbGpPWpGaD
Ranitidine—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	5.12e-05	0.002	CbGpPWpGaD
Ranitidine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.02e-05	0.00196	CbGpPWpGaD
Ranitidine—CYP2D6—Biological oxidations—GSTP1—bone cancer	4.98e-05	0.00194	CbGpPWpGaD
Ranitidine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	4.93e-05	0.00193	CbGpPWpGaD
Ranitidine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	4.91e-05	0.00192	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—NDUFA12—bone cancer	4.91e-05	0.00192	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—GRM1—bone cancer	4.9e-05	0.00191	CbGpPWpGaD
Ranitidine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	4.86e-05	0.0019	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—IL3—bone cancer	4.85e-05	0.00189	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.75e-05	0.00185	CbGpPWpGaD
Ranitidine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.74e-05	0.00185	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.45e-05	0.00174	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.45e-05	0.00174	CbGpPWpGaD
Ranitidine—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	4.29e-05	0.00168	CbGpPWpGaD
Ranitidine—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.22e-05	0.00165	CbGpPWpGaD
Ranitidine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.16e-05	0.00162	CbGpPWpGaD
Ranitidine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.09e-05	0.0016	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—NT5C3A—bone cancer	4.07e-05	0.00159	CbGpPWpGaD
Ranitidine—SLC22A1—Neuronal System—BRAF—bone cancer	3.93e-05	0.00153	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—NDUFA12—bone cancer	3.79e-05	0.00148	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—NDUFA12—bone cancer	3.7e-05	0.00145	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.52e-05	0.00138	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—NDUFA12—bone cancer	3.49e-05	0.00136	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—SMO—bone cancer	3.45e-05	0.00135	CbGpPWpGaD
Ranitidine—SLC22A1—Neuronal System—MDM2—bone cancer	3.29e-05	0.00128	CbGpPWpGaD
Ranitidine—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.25e-05	0.00127	CbGpPWpGaD
Ranitidine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.21e-05	0.00125	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—GNA11—bone cancer	3.16e-05	0.00123	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—NT5C3A—bone cancer	3.14e-05	0.00123	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—NT5C3A—bone cancer	3.07e-05	0.0012	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—NDUFA12—bone cancer	2.96e-05	0.00115	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—ATF1—bone cancer	2.94e-05	0.00115	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—NT5C3A—bone cancer	2.89e-05	0.00113	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—IL3—bone cancer	2.86e-05	0.00112	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.61e-05	0.00102	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.52e-05	0.000983	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—NT5C3A—bone cancer	2.45e-05	0.000957	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—TGFBR2—bone cancer	2.45e-05	0.000956	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—IGF1R—bone cancer	2.3e-05	0.0009	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—ENO2—bone cancer	2.29e-05	0.000895	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—NDUFA12—bone cancer	2.28e-05	0.000891	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.27e-05	0.000886	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—DHFR—bone cancer	2.13e-05	0.000831	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—GNA11—bone cancer	1.99e-05	0.000776	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—NT5C3A—bone cancer	1.89e-05	0.000738	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—CYP3A4—bone cancer	1.8e-05	0.000704	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.78e-05	0.000697	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—ENO2—bone cancer	1.78e-05	0.000696	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—KIT—bone cancer	1.67e-05	0.000652	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—DHFR—bone cancer	1.65e-05	0.000645	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—BRAF—bone cancer	1.57e-05	0.000613	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—GNA11—bone cancer	1.54e-05	0.000603	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—GSTP1—bone cancer	1.54e-05	0.000602	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—EGFR—bone cancer	1.52e-05	0.000594	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.5e-05	0.000585	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—CYP3A4—bone cancer	1.4e-05	0.000547	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—ENO2—bone cancer	1.38e-05	0.000538	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—ENO2—bone cancer	1.34e-05	0.000525	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—MDM2—bone cancer	1.32e-05	0.000514	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—DHFR—bone cancer	1.28e-05	0.000499	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—ENO2—bone cancer	1.27e-05	0.000495	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—DHFR—bone cancer	1.25e-05	0.000487	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—GSTP1—bone cancer	1.2e-05	0.000468	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—GNA11—bone cancer	1.19e-05	0.000466	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—DHFR—bone cancer	1.17e-05	0.000459	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—GNA11—bone cancer	1.17e-05	0.000455	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—JUN—bone cancer	1.14e-05	0.000447	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—MMP9—bone cancer	1.11e-05	0.000435	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—GNA11—bone cancer	1.1e-05	0.000429	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.08e-05	0.000423	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.08e-05	0.000421	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—ENO2—bone cancer	1.07e-05	0.000419	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—CYP3A4—bone cancer	1.06e-05	0.000413	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—CYP3A4—bone cancer	9.95e-06	0.000389	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—DHFR—bone cancer	9.95e-06	0.000389	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—GNA11—bone cancer	9.3e-06	0.000363	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—GSTP1—bone cancer	9.26e-06	0.000361	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—GSTP1—bone cancer	9.03e-06	0.000353	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—EGFR—bone cancer	8.99e-06	0.000351	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—GSTP1—bone cancer	8.51e-06	0.000332	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—CYP3A4—bone cancer	8.43e-06	0.000329	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.39e-06	0.000328	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—ENO2—bone cancer	8.28e-06	0.000323	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—PTGS2—bone cancer	7.98e-06	0.000312	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—DHFR—bone cancer	7.68e-06	0.0003	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—TP53—bone cancer	7.55e-06	0.000295	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—GSTP1—bone cancer	7.21e-06	0.000282	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—GNA11—bone cancer	7.18e-06	0.00028	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—PTGS2—bone cancer	6.2e-06	0.000242	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—GSTP1—bone cancer	5.57e-06	0.000217	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—PTGS2—bone cancer	4.79e-06	0.000187	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—PTGS2—bone cancer	4.68e-06	0.000183	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—PTGS2—bone cancer	4.41e-06	0.000172	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—PTGS2—bone cancer	3.74e-06	0.000146	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—PTGS2—bone cancer	2.88e-06	0.000113	CbGpPWpGaD
